NASDAQ
SKINVIVE by JUVÉDERM® is now the first and only hyaluronic acid injectable approved to reduce horizontal neck lines caused by "tech-neck.1" This is the second FDA-approved indication for SKINVIVE by JUVÉDERM®, which has been approved since 2023 to im...
NORTH CHICAGO, Ill., June 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, ...
The agency's letter cited manufacturing-related items and raised no safety or efficacy concerns. Werschler, a Spokane dermatologist who has served as a clinical trial investigator in dermatology and aesthetic medicine, explains how a Complete Respons...
Data being presented, including six oral presentations, reinforce AbbVie's leadership and commitment to ongoing research to improve outcomes for people living with blood cancers NORTH CHICAGO, Ill., June 8, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) to...
NORTH CHICAGO, Ill., June 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026....
Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trial Fixed-duration VENCLYXTO-based combination regimens prov...
- DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting - DECNUPAZ marks AbbVie's first ADC approved for blood cancer NORTH CHICAGO, I...
The positive opinion is supported by data from the Phase 3 M20-350 study evaluating the safety and efficacy of MAVIRET ® in adults with acute hepatitis C virus (HCV) infection. MAVIRET is a direct-acting antiviral (DAA) treatment currently approved i...
- Data from novel Top1i ADC and T-cell engager platforms highlight potential within solid tumors and blood cancers, including oral presentations in prostate cancer, small cell lung cancer, platinum-resistant ovarian cancer and multiple myeloma - NOR...
Boey ® has received a positive opinion from the CHMP for 30 EU & EEA markets If approved, Boey ® has the potential to be the first and only botulinum neurotoxin serotype E that adult patients can try for the temporary improvement of Glabellar Lines P...
No price data available for this timeframe.